Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as
maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4
cycles of platinum based therapy.
Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus
standard of care alone. Participants who received bevacizumab with their induction
chemotherapy will continue to receive bevacizumab on this study.